Claims for Patent: 10,174,101

Summary for Patent: 10,174,101

Title:	Stable proteins
Abstract:	The invention provides a fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a Family B G-protein coupled receptor (GPCR) that comprises transmembrane helix (TM)-1, TM2 and TM3 of the GPCR; b) a stable protein domain; and c) a second portion of the GPCR comprising TM4, TM5, TM6 and TM7 of the GPCR. The invention also provides a method of crystallizing a GPCR comprising providing the fusion protein of the invention and crystallizing it to obtain crystals.
Inventor(s):	Jazayeri-Dezfuly; Seyed Ali (Hertfordshire, GB), Marshall; Fiona Hamilton (Hertfordshire, GB)
Assignee:	Heptares Therapeutics Limited (Hertfordshire, GB)
Application Number:	14/237,678
Patent Claims:	1. A fusion protein comprising, from N-terminus to C-terminus: a) a first portion of a Family B G-protein coupled receptor (GPCR) that comprises transmembrane helix (TM)-1, TM2 and TM3 of the GPCR, wherein the TM1 and the TM2 are joined by intracellular loop 1 (ICL1), and the TM2 and TM3 are joined by extracellular loop 1 (ECL1); b) a polypeptide selected from the group consisting of a lysozyme, a cytochrome.sub.b562, a flavodoxin, a .beta.-lactamase, and a 70 kDa heat shock ATPase domain; and c) a second portion of the GPCR comprising TM4, TM5, TM6 and TM7 of the GPCR, wherein the TM4 and the TM5 are joined by extracellular loop 2 (ECL2), the TM5 and the TM6 are joined by intracellular loop 3 (ICL3), and the TM6 and the TM7 are joined by extracellular loop 3 (ECL3); wherein the polypeptide is inserted into the intracellular loop 2 (ICL2) region of the GPCR which loop joins the TM3 in the first portion of the GPCR and the TM4 in the second portion of the GPCR, and wherein the fusion protein displays reduced aggregation in the presence of a detergent solution, as compared to a GPCR without insertion of the polypeptide into the ICL2 region of the GPCR. 2. The fusion protein according to claim 1, wherein the polypeptide is inserted into the ICL2 region of the GPCR at a position between amino acid residues that correspond to amino acids Phe 257 and Ser 261 of human GLP1R, wherein Phe 257 corresponds to the fifth amino acid in SEQ ID NO: 30 and Ser 261 corresponds to the ninth amino acid in SEQ ID NO: 30. 3. The fusion protein according to claim 2, wherein the polypeptide is inserted into the ICL2 region of the GPCR after an amino acid corresponding to amino acid Phe 257 of human GLP1R and before an amino acid corresponding to amino acid Ser 261 or Phe 260 or Val 259, wherein Phe 257 corresponds to the fifth amino acid in SEQ ID NO: 30, Ser 261 corresponds to the ninth amino acid in SEQ ID NO:30, Phe 260 corresponds to the eighth amino acid in SEQ ID NO: 30, and Val 259 corresponds to the seventh amino acid in SEQ ID NO: 30. 4. The fusion protein according to claim 2, wherein the polypeptide is inserted into the ICL2 region of the GPCR after an amino acid corresponding to amino acid Ser 258 of human GLP1R and before an amino acid corresponding to amino acid Ser 261 or Phe 260 or Val 259 of human GLP1R, wherein Ser 258 corresponds to the sixth amino acid in SEQ ID NO: 30, Ser 261 corresponds to the ninth amino acid in SEQ ID NO: 30, Phe 260 corresponds to the eighth amino acid in SEQ ID NO: 30, and Val 259 corresponds to the seventh amino acid in SEQ ID NO: 30. 5. The fusion protein according to claim 1, wherein the polypeptide comprises lysozyme. 6. The fusion protein according to claim 1, further comprising a detectable moiety. 7. The fusion protein according to claim 6, wherein the detectable moiety is EGFP. 8. A crystal comprising the fusion protein of claim 1. 9. The fusion protein according to claim 1, which is in a solubilized form or which is substantially free of other proteins or which is immobilized to a solid support. 10. The fusion protein according to claim 1, wherein the Family B GPCR is a glucagon-like peptide 1 receptor (GLP1R), glucagon-like peptide 2 receptor (GLP2R), or glucagon receptor. 11. The fusion protein according to claim 1, wherein the Family B GPCR is a calcitonin receptor (CT). 12. The fusion protein according to claim 1, wherein the Family B GPCR is an amylin/CGRP receptor (AMY.sub.1.alpha.), amylin receptor (AMY.sub.2.alpha.), amylin/CGRP receptor (AMY.sub.3.alpha.), CGRP/adrenomedullin receptor (CGRP.sub.1.alpha.), adrenomedullin/CGRP receptor (AM.sub.1.alpha.), or adrenomedullin/CGRP receptor (AM.sub.2.alpha. receptor). 13. The fusion protein according to claim 1, wherein the Family B GPCR is a corticotropin releasing factor receptor (CRF.sub.1), or urocortins receptor (CRF.sub.2). 14. The fusion protein according to claim 1, wherein the Family B GPCR is a growth hormone releasing hormone receptor (GHRH). 15. The fusion protein according to claim 1, wherein the Family B GPCR is a gastric inhibitory polypeptide receptor (GIP). 16. The fusion protein according to claim 1, wherein the Family B GPCR is a secretin receptor. 17. The fusion protein according to claim 1, wherein the Family B GPCR is a TIP-39 receptor (PTH2), or parathyroid hormone receptor (PTH1). 18. The fusion protein according to claim 1, wherein the Family B GPCR is a VIP/PACAP receptor (VPAC.sub.1), PACAP receptor (PAC.sub.2), or VIP/PACAP receptor (VPAC.sub.2). 19. The fusion protein according to claim 1, wherein the polypeptide is a lysozyme and wherein the amino acid sequence of the lysozyme is at least 90% identical to SEQ ID NO: 24. 20. The fusion protein according to claim 5, wherein the lysozyme is T4 lysozyme. 21. The fusion protein according to claim 6, wherein the detectable moiety is a fluorescent label, a radiolabel, or an enzymatic label.

Details for Patent 10,174,101

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2031-08-10